You are here

Our science / Clinical Trials / Find a Trial / NCT00174434

Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

Back to Search Print Save as PDF Bookmark Trial

NCT00174434

Last updated on February 17, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Harvey, Illinois, 60426-4265 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.

- Candidate for treatment with paclitaxel.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior chemotherapy in the advanced disease setting.

- HER2 positive disease unless previously treated with trastuzumab.

NCT00174434
Pfizer
Completed
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Advanced or Recurrent Solid Tumors, Breast Neoplasms, Epithelial Ovarian Cancer, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
NCT01286987
All Genders
18+
Years
Multiple Sites
Neoplasms, Non Small Cell Lung Carcinoma, Breast Neoplasms, Ovarian Neoplasms
A Study Of PF-06263507 In Patients With Advanced Solid Tumors
NCT01891669
All Genders
18+
Years
Multiple Sites
Breast Neoplasms
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
NCT02297438
Females
18+
Years
Multiple Sites
Breast Neoplasms
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
NCT00062751
Females

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now